We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients HARSHMAN ET AL. RRM1 EXPRESSION IN MUSCLE-INVASIVE UROTHELIAL CANCER.
- Authors
Harshman, Lauren C.; Bepler, Gerold; Zhong Zheng; Higgins, John P.; Allen, Genevera I.; Srinivas, Sandy
- Abstract
OBJECTIVE To assess whether high ribonucleotide reductase subunit M1 (RRM1) expression in patients with resected, muscle-invasive (T2- 4NxM0) urothelial carcinoma (UC) correlated with longer overall survival (OS). RRM1 is the primary cellular target of gemcitabine and previous studies in resected early-stage lung cancer have shown a survival benefit for patients with high expression. PATIENTS AND METHODS In all, 84 radical cystectomy specimens with muscle-invasive UC were identified from existing tissue microarrays. The patients' medical records were retrospectively reviewed to confirm pathology and stage. Specimens were analysed for RRM1 expression using automated quantitative analysis. The median value of RRM1 was established a priori as the threshold for high and low expression. RESULTS The median age of the patients was 69 years. Stages were nearly equally distributed: 30%, 38%, and 32% for stage II, III, and IV, respectively. Most were high grade (99%) with no nodal involvement (69%). The median (range) OS was 2.0 (0-13.1) years. Tumoral RRM1 levels did not correlate with OS for the entire cohort, but when adjusted for age, high tumoral RRM1 expression in younger patients (aged < 70 years) correlated with increased survival. Younger patients with high RRM1 expression had a median OS of 10.6 years compared with 1.6 years in older patients ( P = 0.001). There was no difference in OS among low RRM1 expressors: 2.3 vs 1.6 years in younger and older patients, respectively ( P = 0.22). CONCLUSIONS Our results suggest that high RRM1 expression may be prognostic for improved survival in patients with muscle-invasive UC aged < 70 years.
- Subjects
CANCER patients; BLADDER cancer; DEOXYRIBONUCLEOTIDES; OLD age; MEDICAL care
- Publication
BJU International, 2010, Vol 106, Issue 11, p1805
- ISSN
1464-4096
- Publication type
Article
- DOI
10.1111/j.1464-410X.2010.09327.x